Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusion - An experimental study in dogs

European Journal of Surgical Oncology

Volumn 23, Issue 5, 1997, Pages 439-444

  Pfeiffer, T ^a,b   Krause, U ^a   Thome, U ^a   Rajewski, A ^a   Skorzek, M ^a   Scheulen, M E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Doxorubicin; Isolated perfusion; Pharmacokinetics; Regional chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; INTERSTITIUM; INTRAARTERIAL DRUG ADMINISTRATION; LIMB PERFUSION; MICROCIRCULATION; MUSCLE LEVEL; NONHUMAN; PRIORITY JOURNAL; TOXICITY;

EID: 0030780362     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)93727-6     Document Type: Article

References (37)

1. Braat RP, Wieberdink J, van Slooten E, Olthuis G. Regional perfusion with adriamycin in soft tissue sarcoma. Recent Results Cancer Res 1983; 86: 260-3.
2. Tate PS, Djuric M, Bies J. Pharmacokinetics of doxorubicin in heated perfusion of canina extremities. Proc Animal Meeting Am Ass Cancer Res (AACR) 1986; 27: 406-7.
3. Briele HA, Djuric M, Walker MJ, Chaudhuri PK, Beattie CW, Das Gupta TK. Kinetics and toxicity of doxorubicin (Adriamycin A) in isolation perfusion of canine hind limbs. Surgical Forum 1991; 31: 429-30.
4. Kraus TW, Mross K, Hamm K, Kettelhack C, Hossfeld DK, Schlag P. Pharmacokinetics of doxorubicin in the heparinized perfusate during isolated hyperthermic limb perfusion. Onkologie 1993; 16: 16-21.
5. Klaase JM, Kroon BB, Benckhuijsen C, van Geel AN, Albus Lutter CE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616-21.
6. Wieberdink J, Benckhuysen C, Braat RP, Van Slooten RA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905.
7. Pfeiffer T, Krause U, Thome U, Skorzek M, Scheulen ME. Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion. Eur J Surg Oncol 1995; 21: 551-4.
8. Robert J. Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 1980; 3: 1561-72.
9. Camaggi CM, Comparsi K, Strocchi E, Testoni F, Pannuti F. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 1988; 21: 216-20.
10. Lawrence WJ, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas: a pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205: 349-59.
11. Emrich LJ, Ruka W, Driscoll DL, Karakousis CP. The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas. J Clin Epidemiol 1989; 42: 105-10.
12. McBride CM. Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974; 109: 304-10.
13. Schraffordt Koops H, Eibergen R, Oldhoff J, van der Ploeg E, Vermey A. Isolated regional perfusion in the treatment of soft tissue sarcomas of the extremities. Clin Oncol 1976; 2: 245-6.
14. Lindberg R. Treatment of localized soft tissue sarcomas in adults at M. D. Anderson Hospital and Tumor Institute (1960-81). Cancer Treat Symp 1985; 3: 59-65.
15. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 1991; 214: 328-38.
16. Aigner K, Schwemmle K. (Technic of isolated perfusion of the extremities. Experience with 171 cases) Langenbecks Arch Chir 1983; 359: 113-22.
17. Tonak J, Hohenberger W, Gohl J. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas]. Chirurgie 1984; 55: 499-504.
18. Henneking K, Aigner K, Deeg C, Merker G, Spelz HW, Hundeiker M. Tissue toxicity in experimental isolated perfusion with adriamycin. Recent Results Cancer Res 1983; 86: 254-9.
19. Di Filippo F, Giannarelli D, Botti C, et al. Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. Ann Oncol 1992; 3 (Suppl 2): S71-4.
20. Rossi CR, Vecchiato A, Da Pian PP, et al. Adriamycin in hyperthermic perfusion for advanced limb sarcomas. Ann Oncol 1992; 3 (Suppl 2): S111-3.
21. Sigurdsson GH, Nachbur B, Lejeune FJ. Anesthesiologists' management of isolated limb perfusion with 'high-dose' tumor necrosis factor alpha. Anesthesiology 1993; 79: 1433-7.
22. Kettelhack C, Kraus T, Hupp T, Manner M, Schlag P. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990; 16: 370-5.
23. Roseman JM. Cisplatin in isolated limb perfusion. Am J Surg 1989; 157: 366.
24. Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155: 667-71.
25. Fletcher WS, Pommier RF, Woltering EA, Mueller CR, Ash KO, Small KA. Pharmacokinetics and results of dose escalation in cis-platin hyperthermic isolation limb perfusion. Am Surg Oncol 1994; 1: 236-43.
26. Aigner K, Hild P, Breithaupt H, et al. Isolated extremity perfusion with DTIC. An experimental and clinical study. Anticancer Res 1983; 3: 87-93.
27. Lejeune FJ, Lienard D, Ewalenko P. Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas. World J Surg 1988; 12: 345-8.
28. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986; 162: 149-52.
29. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987; 60: 1703-7.
30. Roseman JM, Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. J Surg Oncol 1987; 35: 170-2.
31. Krementz ET. Regional perfusion: current sophistication, what next. Cancer 1986; 57: 416.
32. Eichfeld U, Glaser A, Schneider G, Kraus J, Pauer HJ, Schwarz I. (Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma - therapeutic applications and results). Zentralbl Chir 1993; 118: 63-8.
33. Eggermont AMM, Schraffordt Koops H, Kroon BBR, et al. 90% limb salvage by isolated limb perfusion with high dose TNF alfa, IFN-gamma and melphalan for irresectable soft tissue sarcomas. Eur J Surg Oncol 1994; 20: 322 (Abstract).
34. Lejeune F, Lienard D, Eggermont A, et al. (Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience). Bull Cancer Paris 1995; 82: 561-7.
35. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
36. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80: 995-7.
37. Hill S, Thomas JM. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res 1994; 4 (Suppl 1): 31-4.